Urinary Antigen Testing for Respiratory Infections: Current Perspectives on Utility and Limitations

20Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Pneumonia is a leading cause of hospitalization and death due to infection worldwide. Streptococcus pneumoniae and Legionella pneumophila remain among the most commonly identified bacterial pathogens. Unfortunately, more than half of all pneumonia cases today lack an etiologic diagnosis due to limitations in traditional microbiological methods like blood and sputum cultures, which are affected by poor sample collection, prior antibiotic administration, and delayed processing. Urinary antigen tests (UATs) for S. pneumoniae and L. pneumophila have emerged as powerful tools for improving the diagnosis of bacterial respiratory infections, enabling physicians to administer early directed therapy and improve antimicrobial stewardship. UATs are simple, rapid, and non-invasive diagnostic tests with high specificity (>90%) and moderate sensitivity (<80%). The potential impact of urinary antigen testing is especially significant for respiratory infections caused by Legionella. While all recommended community-acquired pneumonia (CAP) therapies are adequate for treating pneumococcal pneumonia, only certain antibiotics are effective against Legionella. Delayed therapy for Legionella is associated with worse clinical outcomes, which underscores the importance of rapid diagnostic methods like UATs. Despite their potential impact, current American Thoracic Society and Infectious Diseases Society of America (ATS/IDSA) guidelines argue against the routine use of urinary antigen testing for S. pneumoniae and L. pneumophila, except in patients with severe CAP and those with epidemiological risk factors for Legionella. Further research is necessary to evaluate the impact of early targeted treatment due to positive UAT results, as well as optimal strategies for UAT utilization. The purpose of this review is to summarize the UATs available for bacterial respiratory infections, describe current guidelines on their usage, and assess their impact on clinical outcomes and targeted therapy.

References Powered by Scopus

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults

5182Citations
N/AReaders
Get full text

Diagnosis and treatment of adults with community-acquired pneumonia

2287Citations
N/AReaders
Get full text

Community-acquired pneumonia requiring hospitalization among U.S. adults

1801Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)

10Citations
N/AReaders
Get full text

Legionella pneumophila Infections during a 7-Year Retrospective Analysis (2016–2022): Epidemiological, Clinical Features and Outcomes in Patients with Legionnaires’ Disease

6Citations
N/AReaders
Get full text

Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kim, P., Deshpande, A., & Rothberg, M. B. (2022). Urinary Antigen Testing for Respiratory Infections: Current Perspectives on Utility and Limitations. Infection and Drug Resistance. Dove Medical Press Ltd. https://doi.org/10.2147/IDR.S321168

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

68%

Researcher 3

16%

Professor / Associate Prof. 2

11%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

68%

Engineering 2

11%

Agricultural and Biological Sciences 2

11%

Immunology and Microbiology 2

11%

Save time finding and organizing research with Mendeley

Sign up for free